A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC

INTRODUCTION: L-DOS47, a targeted urease–anti-CEACAM6 immunoconjugate, alters the acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the cytotoxic effects of L-DOS47 were additive when combined with pemetrexed and carboplatin. METHODS: This phase I, open-label, d...

Descripción completa

Detalles Bibliográficos
Autores principales: Piha-Paul, Sarina, Simon, George, Belani, Chandra P., Chao, Heman, Gaspar, Kim, Lee, Brenda, Dowlati, Afshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576893/
https://www.ncbi.nlm.nih.gov/pubmed/36268537
http://dx.doi.org/10.1016/j.jtocrr.2022.100408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576893/
https://www.ncbi.nlm.nih.gov/pubmed/36268537
http://dx.doi.org/10.1016/j.jtocrr.2022.100408

Ejemplares similares